Results 211 to 220 of about 87,373 (338)

Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.

, 1988
Clay B. Siegall, V K Chaudhary, David Fitzgerald, Ira Pastan   +3 more
openalex   +1 more source

PROTEINS IN MULTIPLE MYELOMA [PDF]

Journal of Biological Chemistry, 1956
Aiko Miyake, Frank W. Putnam, Franz Meyer   +2 more
openaire   +2 more sources

Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial

British Journal of Haematology, EarlyView.
Graham McIlroy, Hannah V. Giles, Amy Rollins, Gemma Malin, Libby Jones, Nicola J. Wright, Oscar Berlanga, Simon North, Mark Cook, Colin Hutchison, Nils Heyne, Katja Weisel, Jennifer Pinney, Stephen Harding, Paul Cockwell, Guy Pratt   +15 more
wiley   +1 more source

Membraneless Organelles and Phase Separation in Tumours: Mechanisms and Prospects

Cell Proliferation, EarlyView.
The Salient and Novel Findings: This article summarises the latest research advancements in phase separation within tumours, with a particular focus on the role and molecular mechanisms of liquid–liquid phase separation (LLPS) in tumour progression.
Hao Yang, Zhong Chu, Shuwen Han, Yuefen Pan   +3 more
wiley   +1 more source

Chemotherapy-Mediated Induction of PD-L1 via SEI1 Facilitates Myeloma Immune Evasion. [PDF]

Adv Sci (Weinh)
Chen R, Li Z, Fang Z, Li Z, Yang D, Li Y, Liu S, Liu Z, Liu R, Liu H.   +9 more
europepmc   +1 more source

Binding of Rabbit Antibodies to a Mouse Myeloma Protein by the Myeloma Cells in Vitro

Experimental Biology and Medicine, 1970
openaire   +3 more sources

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

Cell Proliferation, EarlyView.
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang   +5 more
wiley   +1 more source

Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective. [PDF]

Clinicoecon Outcomes Res
Siegfried C, Amarapala M, Leleu X, Fusfeld L.   +3 more
europepmc   +1 more source

RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA

Cell Proliferation, EarlyView.
Targeting RBM39 attenuates BER via destabilising OGG1 mRNA and potentiates KBrO3‐induced oxidative stress in HCC. Our study represents a valuable treatment strategy combining indisulam and an oxidative stress inducer in HCC. ABSTRACT Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics.
Hongda An, Anliang Xia, Siyuan Liu, Dongjun Luo, Longpo Geng, Binghua Li, Beicheng Sun, Zhu Xu   +7 more
wiley   +1 more source

Comprehensive Analysis Identifies Hsa_circ_0058191 as a Potential Drug Resistance Target in Multiple Myeloma. [PDF]

Onco Targets Ther
Yang H, Zhu J, Wang X.
europepmc   +1 more source